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Objective: To compare the outcome of patients undergoing
autologous peripheral blood stem cell transplantation
(PBSCT) conditioned with FluBuTBI or BEAM (BCNU, Etopo-
side, Cytarabine, and Melphalan) at our institution.
Patients and Methods: We conducted a retrospective
analysis of patients (n¼101) who underwent autologous
PBSCT at our institution and were conditioned with BEAM
(n¼63) or FluBuTBI (n¼38) between January 2006 and
December 2012. Recipients were classiﬁed according to
CIBMTR criteria and those conditioned with BEAM were
low risk (n¼17) and intermediate risk (n¼46). Recipients
conditioned with FluBuTBI were low risk (n¼9), interme-
diate risk (n¼25), and high risk (n¼4). Median age of pa-
tients in the BEAM group was 52.3 years compared to 59.6
years for FluBuTBI. At the time of transplantation, 38 of 63
patients who received BEAM were in complete remission
(60%) compared to 19 of 38 patients (50%) for FluBuTBI.
Median time of follow up was 57 months for BEAM and 24
months for FluBuTBI.
FluBuTBI consisted of intravenous (IV) Fludarabine 50mg/
m2/day infused over 1 hour on days -6 through -2, IV
Busulfan 3.2 mg/kg/day on days -5 through -2 (infusion rate
80 mg/kg/hour) and TBI 200 cGy on days -2 and -1. BEAM
regimen consisted of IV BCNU 300 mg/m2 infused over 1 hr
on day -5, Etoposide 200 mg/m2/day over 3 hours on days -5
through -2, Cytarabine 200 mg/m2/day over 1 hour every 12
hours on days -5 through -2, and Melphalan 140 mg/m2over
1 hr on day -1. Diagnoses were Hodgkin’s lymphoma (n¼26),
B-cell lymphoma NOS (n¼3), anaplastic large cell lymphoma
(n¼2), Burkitt’s lymphoma (n¼3), diffuse large B-cell lym-
phoma (n¼ 23), follicular lymphoma (n¼16), mantle cell
lymphoma (n¼22), peripheral T-cell lymphoma (n¼5),
transformed follicular lymphoma (n¼1).
Results: Overall survival at 3 years for patients undergoing
BEAM was 71% and for FluBuTBI 72%. Cumulative incidence
of disease progression or relapse at 3 years for BEAMwas 39%
compared to 32% for the FluBuTBI group. Treatment related
mortality was 3% (n¼2) in the BEAM group and 0% in the
FluBuTBI group. Treatment related MDS/AML occurred in 6%
(n¼4) in the BEAM group compared to 2% (n¼1) in the Flu-
BuTBI group. Grade 3-4 mucositis was seen in 16% (n¼6) in
the FluBuTBI group compared to 4% (n¼3) in the BEAM
group.
Conclusion: Comparison of the two groups showed identical
overall survival at 3 years, but a trend to reduced relapse,
treatment related mortality and secondary MDS/AML, in
patients conditioned with FluBuTBI. This difference was
present despite older and higher risk patients in the FluBuTBI
group. Mucositis was more frequent in the FluBuTBI group.
Conditioning with FluBuTBI is a safe and effective alternative
to BEAM for autologous PBSCT that offers the potential for
further optimization by study of Busulfan pharmacokinetics
and the introduction of targeted radiation.133
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Evaluate the genotoxicity and oxidative status in patients
undergoing autologous HSCT, different moments comparing
pre-and post-transplantation. The study is a prospective
longitudinal in order to investigate the genotoxicity and
oxidative status in adult patients Undergoing autologous
HSCT, accompanied in the service of Hematology, University
Hospital Walter Cantídio (HUWC), and healthy subjects from
January 2013 to August 2013. The study consisted of control
(n ¼ 30) consisted of healthy volunteers, adults, matched by
sex and age with the patients group. Only one sample was
collected from volunteers. Patients (n¼30) with oncohema-
tologic diseases (multiple myeloma, non-Hodgkin lym-
phoma and Hodgkin lymphoma) that meet the basic
conditions to the completion of the service accompanied
HSCT Hematology HUWC. Determine the concentration of
MDA (malondialdehyde), enzyme superoxide dismutase
(SOD) and in the DI (damage index) were performed before
the CR(conditioning regimen) (CR Pre), 24 hours after the CR
(D - 1), 1 day (D +1), 10 days (D +10 ) and 20 ( D +20 ) days
after autologous HSCT. The determination of MDA based on
its reaction with thiobarbituric acid (TBARS) in heparinized
plasma and measuring the activity of superoxide dismutase
(SOD) in erythrocytes were determined by spectrometry and
comet assay, or technique of cell microgel electrophoresis
was used to assess DNA damage. Statistical analysis was
performed using GraphPad Prism. We used the ANOVA test
for comparison of patients groups and controls. The level of
signiﬁcance is 5 % (p < .05). MDA levels in patients Under-
going HSCT between and control (p< .0001) and between
D-1 and other groups (p < .0001). Levels of the antioxidant
enzyme SOD in patients between control and pre CR (p ¼
.0048), control and D- 1 (p < .0001), and between control
and D +20 (p ¼ .0271), between Pre and D +1 CR (p < .0001)
between D-1 and D +1 (p < .0001), D +10 and D+20
(p<.0001). An increase in ID in patient samples compared to
controls. There was a signiﬁcant increase in damage index 24
hours after the conditioning regimen (D-1) (56.63  15.57)
when compared to the control group (4.935  2.038) and at
other times examined. Results support the hypothesis stated
HSCT induces an Increase in oxidative stress either by
increased production of free radicals and by reduction of
antioxidant enzymes with consequent damage of the DNA.134
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Plerixafor allows for rapid mobilization of hematopoietic
stem cells (HSCs) by disrupting the interaction of HSC re-
ceptor CXCR4 and bone marrow stromal cytokine SDF-1
alpha. When combined with granulocyte colony stimulating
factor (G-CSF) with or without chemotherapy, rates of suc-
cessful mobilization are increased in patients who have
previously failed to mobilize or have traits predictive of
failure. Current package labeling for plerixafor states that
leukapharesis (LP) should begin 10-11 hours post adminis-
tration, the time at which peak peripheral blood (PB) CD34+
cell counts have been observed. Phase I data in healthy vol-
unteers shows that peak PB CD34+ cell count is dose
dependent and that counts increase in a linear fashion be-
tween hours 1,3,6 and 9. Studies in HLA-matched sibling
donors have shown that minimum required yield for trans-
plant can be reached when LP begins 4 hours after plerixafor
injection. In our institution, due to time constraints, we
follow a model consistent with these previous studies and
begin LP 4-6 hours after plerixafor injection. In order to
assess efﬁcacy of this timing in patients undergoing autolo-
gous stem cell transplant (autoSCT), we completed a retro-
spective chart review of 43 patients; 25 with lymphoma and
18 with multiple myeloma (MM). The median percent
change in PB CD34+ cell count, prior to 1stLP, was 19.9% in
lymphoma and 13.45% in MM. 95% of patients reached the
minimumyield required for autoSCT in 4 days. One patient
with MM and one patient with lymphoma failed to collect
adequate levels of HSCs. The median total CD34+ yield was
4.33x106 and 6.73x106 in the lymphoma and MM groups
respectively. All but ﬁve patients proceeded to autoSCT.
Among the 38 patients that remained eligible for autoSCT,
themedian number of days for ANC and platelet engraftment
was 11 and 22 respectively. These results are comparable to
historical data, thus showing that high risk patients can
collect an adequate number of stem cells, in an expected
period of time, with good engraftment results using an
alternative plerixafor mobilization schedule.135
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Background: CD34+ cell-doses given during autologous
stem cell transplantation (ASCT) for multiple myeloma (MM)
patients (pts) can vary between pts depending on ability to
mobilize CD34+ cells and amount of CD34+ cells/kg collected
during the apheresis procedure. Published retrospective
studies suggest that absolute lymphocyte count (ALC) re-
covery may be a predictor of overall survival (OS), progres-
sion free survival (PFS), and infectious complications in ASCT.
It is unclear whether there is an optimal CD34+ cell-dose that
correlates with a shorter time to ALC recovery, possiblydecreasing infectious complications, and potentially
increasing time to relapse.
Methods: A retrospective analysis of ALC recovery was per-
formed on 12 consecutive MM pts who had undergone ASCT
from 1/2012 to 1/2013 at the University of Virginia to
determine if a relationship existed between CD34+ cell-dose
given during ASCT and ALC recovery. For each pt, number/
type of infection and ALCs were collected for the ﬁrst 100
days post-ASCT. OS and PFS were also assessed for each pt.
Cox proportional hazard models were used to estimate the
association of CD34+ cell-dose infused with time to ALC re-
covery after ASCT. ALC recovery was deﬁned as the ﬁrst day
of three consecutive measurements for three different cutoff
values: ALC  800, ALC  1000, and ALC  1500. No
competing risks occurred; therefore, the log rank test sta-
tistic was used to assess the signiﬁcance of the association.
Results: Median age was 60 years (range from 45-71 years),
75% were male, 67% had IgG MM, and 92% had kappa light
chain restriction. Fifty-eight percent had ISS Stage I MM and
33% had ISS Stage III disease. The analysis revealed that a
higher CD34+ cell-dose given during ASCT showed a trend
toward faster ALC recovery, when deﬁned as ALC  800
(p¼.043) and ALC  1000 (p¼.052). No difference was seen
for ALC  1500. Median times to achieving ALC  800 and
ALC  1000 were 43 and 59 days, respectively for pts given
CD34+ cell-dose < 4x106 cells/kg; and were 18 and 19 days
for pts given CD34+ cell-dose > 4x106 cells/kg. All ﬁve pts
transplanted with a CD34+ cell-dose < 4x106 cells/kg
developed at least one bacterial infection. Only one of the
seven pts transplantedwith CD34+ cell-dose> 4x106 cells/kg
developed bacterial complications. Eighty-two percent of
bacterial infections (n¼11) occurred in pts given CD34+ cell-
dose < 4x106cells/kg. Median time of follow-up was 12
months (range from 9 to 20 months). Two pts have relapsed,
at 10 and 13months, post-ASCTand no deaths have occurred.
Conclusion: These preliminary results suggest that CD34+
cell-dose > 4x106 cells/kg given during ASCT for MMmay be
associated with shorter ALC recovery and lower rates of in-
fections. However, larger prospective trials with longer
follow-up are necessary to further deﬁne optimal CD34+ cell-
dose infusion for ASCT in MM pts in order to improve ALC
recovery.136
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Background: The role of radiological surveillance with
Positron Emission Tomography (PET) or Computed Tomog-
raphy (CT) after completion of chemotherapy in patients
with lymphoma is controversial. Prior studies have shown
conﬂicting results in regards to the beneﬁt of screening for
patients with lymphoma using CT or PET versus clinical
detection of relapse. What is not known is whether
